Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children

International Journal of Infectious Diseases

Volumn 16, Issue 11, 2012, Pages

  Punpanich, Warunee ^a   Nithitamsakun, Natthacha ^a   Treeratweeraphong, Vipa ^b   Suntarattiwong, Piyarat ^a  

^a RANGSIT UNIVERSITY   (Thailand)

^b QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

Author keywords

Acinetobacter baumannii; Bacteremia; Carbapenem non susceptibility; Children; Risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; CARBAPENEM; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PENICILLIN G; QUINOLONE; SULBACTAM;

ACINETOBACTER BAUMANNII; ACINETOBACTER BAUMANNII BACTEREMIA; ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL STRAIN; CHILD; DISEASE ASSOCIATION; FEMALE; HUMAN; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; BACTEREMIA; CARBAPENEMS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THAILAND;

EID: 84868208889     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.07.006     Document Type: Article

References (34)

1. Siegel R.E. Emerging Gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Respir Care 2008, 53:471-479.
2. Paterson D.L. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006, 43(Suppl 2):S43-S48.
3. Bonomo R.A., Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006, 43(Suppl 2):S49-S56.
4. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582.
5. Goldstein B., Giroir B., Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005, 6:2-8.
6. Cockerill F., Wikler M., Bush K., Dudley M., Eliopoulos G., Hardy D., et al. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. M100-S20 2010, CLSI, Wayne, PA.
7. Gales A.C., Reis A.O., Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001, 39:183-190.
8. Hortiwakul T., Chayakul P., Ingviya N., Chayakul V. In vitro activity of colistin, fosfomycin, and piperacillin/tazobactam against Acinetobacter baumannii and Pseudomonas aeruginosa in Songklanagarind Hospital, Thailand. J Infect Dis Antimicrob Agents 2009, 26:91-96.
9. Hu J., Robinson J.L. Systematic review of invasive Acinetobacter infections in children. Can J Infect Dis Med Microbiol 2010, 21:83-88.
10. Cisneros J.M., Reyes M.J., Pachon J., Becerril B., Caballero F.J., Garcia-Garmendia J.L., et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996, 22:1026-1032.
11. Bonsu B.K., Chb M., Harper M.B. Identifying febrile young infants with bacteremia: is the peripheral white blood cell count an accurate screen?. Ann Emerg Med 2003, 42:216-225.
12. Kuppermann N., Fleisher G.R., Jaffe D.M. Predictors of occult pneumococcal bacteremia in young febrile children. Ann Emerg Med 1998, 31:679-687.
13. Carey R, Banerjee S, Srinivasan A. Multidrug-resistant Acinetobacter infections, 1995-2004. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, September 27-30, 2006.
14. Mera R.M., Miller L.A., Amrine-Madsen H., Sahm D.F. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010, 16:209-215.
15. National Antimicrobial Resistance Surveillance Center Thailand. Percent susceptibility of A. baumannii to imipenem 2010. Bangkok: NARST; 2010 Available at: (accessed January 24, 2010). http://narst.dmsc.moph.go.th/.
16. Routsi C., Pratikaki M., Platsouka E., Sotiropoulou C., Nanas S., Markaki V., et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010, 38:173-180.
17. Baran G., Erbay A., Bodur H., Onguru P., Akinci E., Balaban N., et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008, 12:16-21.
18. Dent L.L., Marshall D.R., Pratap S., Hulette R.B. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis 2010, 10:196.
19. Anunnatsiri S., Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. Southeast Asian J Trop Med Public Health 2011, 42:693-703.
20. Shih M.J., Lee N.Y., Lee H.C., Chang C.M., Wu C.J., Chen P.L., et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study. J Microbiol Immunol Infect 2008, 41:118-123.
21. Falagas M.E., Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006, 64:7-15.
22. Lautenbach E., Synnestvedt M., Weiner M.G., Bilker W.B., Vo L., Schein J., et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009, 30:1186-1192.
23. Lim S.K., Lee S.O., Choi S.H., Choi J.P., Kim S.H., Jeong J.Y., et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci 2011, 26:325-331.
24. Sunenshine R.H., Wright M.O., Maragakis L.L., Harris A.D., Song X., Hebden J., et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13:97-103.
25. Daniels T.L., Deppen S., Arbogast P.G., Griffin M.R., Schaffner W., Talbot T.R. Mortality rates associated with multidrug-resistant Acinetobacter baumannii infection in surgical intensive care units. Infect Control Hosp Epidemiol 2008, 29:1080-1083.
26. Abbo A., Carmeli Y., Navon-Venezia S., Siegman-Igra Y., Schwaber M.J. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007, 26:793-800.
27. Sheng W.H., Liao C.H., Lauderdale T.L., Ko W.C., Chen Y.S., Liu J.W., et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 2010, 14:e764-e769.
28. Lee N.Y., Lee H.C., Ko N.Y., Chang C.M., Shih H.I., Wu C.J., et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007, 28:713-719.
29. Tan T.Y., Ng L.S. Comparison of three standardized disc susceptibility testing methods for colistin. J Antimicrob Chemother 2006, 58:864-867.
30. Galani I., Kontopidou F., Souli M., Rekatsina P.D., Koratzanis E., Deliolanis J., et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008, 31:434-439.
31. Maalej S.M., Meziou M.R., Rhimi F.M., Hammami A. Comparison of disc diffusion, Etest and agar dilution for susceptibility testing of colistin against Enterobacteriaceae. Lett Appl Microbiol 2011, 53:546-551.
32. Moreno S., Vicente T., Armas M., Bernaldo de Quiros J.C., Rodriguez-Creixems M., Bouza E. [Nosocomial bacteremia caused by Acinetobacter]. Enferm Infecc Microbiol Clin 1990, 8:606-609.
33. Seifert H., Strate A., Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995, 74:340-349.
34. Tilley P.A., Roberts F.J. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis 1994, 18:896-900.